Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | CRHBP | P24387 | 1/20 | 0.57 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | ITGA4 | P13612 | 6/20 | 0.49 |
| ▸ | ITGB7 | P26010 | 6/20 | 0.49 |
| ▸ | NQO2 | P16083 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4864240 | 0.90 | MEN1 (0.52) | KMT2AMEN1CRHBPCRHR2TDP1 | |
| SCHEMBL11193465 | 0.85 | NQO2 (0.48) | KMT2AMEN1CRHBPCRHR2NQO2 | |
| SCHEMBL11192327 | 0.85 | ALDH1A1 (0.50) | KMT2AMEN1TDP1NQO2NPC1 | |
| SCHEMBL6675975 | 0.85 | NQO2 (0.48) | KMT2AMEN1CRHBPCRHR2TDP1 | |
| SCHEMBL7500051 | 0.84 | KMT2A (0.59) | KMT2AMEN1NQO2NPC1RAB9A | |
| SCHEMBL5170527 | 0.83 | CTSB (0.54) | KMT2AMEN1CRHBPCRHR2TDP1 | |
| SCHEMBL9827138 | 0.82 | KMT2A (0.55) | KMT2AMEN1CRHBPCRHR2TDP1 | |
| SCHEMBL25735701 | 0.82 | NQO2 (0.46) | KMT2AMEN1CRHBPCRHR2NQO2 | |
| SCHEMBL9212980 | 0.82 | SMN1; SMN2 (0.52) | KMT2AMEN1NQO2NPC1RAB9A | |
| SCHEMBL11509750 | 0.82 | APP (0.56) | KMT2AMEN1CRHBPCRHR2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040266839-A1 | 2'-Methyl-5-(1,3,4-oxadiazol-2-yl)1,1'-biphenyl-4-carboxaide derivatives and their use as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2004-12-30 | — | — | US | disclosed |
| EP-1310479-B1 | Process for the preparation of 2-aminomethyl-1,4-diamino-benzene and salts thereof | WELLA AG (DE) | 2004-10-27 | — | — | EP | disclosed |
| EP-1435949-A1 | 2' -METHYL-5-(1,3,4-OXADIAZOL-2-YL)-1,1'-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-07-14 | — | — | EP | disclosed |
| EP-1310479-A1 | Process for the preparation of 2-aminomethyl-1,4-diamino-benzene and salts thereof | Wella Aktiengesellschaft (DE) | 2003-05-14 | — | — | EP | disclosed |
| WO-2003032986-A1 | 2' -METHYL-5-(1,3,4-OXADIAZOL-2-YL)-1,1'-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-04-24 | — | — | WO | disclosed |
| US-6461390-B1 | Process for making 2-aminomethyl-1, 4-diaminobenzene and its salts and compositions and methods for dyeing keratin fibers using same | WELLA AKTIENGESELLSCHAFT (DE) | 2002-10-08 | — | — | US | disclosed |
| EP-1110942-A2 | Process for the preparation of 2-aminomethyl-1,4-diamino-benzene and salts thereof, and their use in dyeing composition for keratin fibers | Wella Aktiengesellschaft (DE) | 2001-06-27 | — | — | EP | disclosed |
| EP-0226072-B1 | OXIDATION DYE CONTAINING 4-AMINO-2-AMINOMETHYL PHENOL | Wella Aktiengesellschaft (DE) | 1991-04-10 | — | — | EP | disclosed |
| US-4797130-A | DYE DEVELOPERS GOOD FOR RED COLORING | WELLA AKTIENGESELLSCHAFT (DE) | 1989-01-10 | — | — | US | disclosed |
| EP-0226072-A1 | Oxidation dye containing 4-amino-2-aminomethyl phenol | Wella Aktiengesellschaft (DE) | 1987-06-24 | — | — | EP | disclosed |
| WO-1987003475-A2 | OXIDIZING HAIR DYER BASED ON 4-AMINO-2-AMINOMETHYLPHENOLS | WELLA AKTIENGESELLSCHAFT (DE) | 1987-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266839-A1 | 2'-Methyl-5-(1,3,4-oxadiazol-2-yl)1,1'-biphenyl-4-carboxaide derivatives and their use as p38 kinase inhibitors | MAPK1, MAPK3, MAPK6 | KMT2A 702/4885MEN1 3865/4885CRHBP 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.